

# Athene Lane

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6022048/publications.pdf>

Version: 2024-02-01

120  
papers

6,652  
citations

147566

31  
h-index

66788

78  
g-index

121  
all docs

121  
docs citations

121  
times ranked

9206  
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing an online, searchable database to systematically map and organise current literature on retention research (ORRCA2). <i>Clinical Trials</i> , 2022, 19, 71-80.	0.7	5
2	Qualitative Assessment of the Conservative Management of Nocturia with Standardised Written Materials for Lower Urinary Tract Symptoms in Men Treated in Primary Care. <i>European Urology Focus</i> , 2022, , .	1.6	2
3	Use of the International Consultation on Incontinence Questionnaires Bladder Diary in Men Seeking therapy for Lower Urinary Tract Symptoms. <i>European Urology Focus</i> , 2022, 8, 66-74.	1.6	5
4	Prostate Surgery for Men with Lower Urinary Tract Symptoms: Do We Need Urodynamics to Find the Right Candidates? Exploratory Findings from the UPSTREAM Trial. <i>European Urology Focus</i> , 2022, 8, 1331-1339.	1.6	11
5	The importance of overcoming the challenges in delivering the Proper Understanding of Recurrent Stress Urinary Incontinence Treatment (PURSUIT) study. , 2022, 1, 100020.		1
6	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	23
7	Increased transparency was required when reporting imputation of primary outcome data in clinical trials. <i>Journal of Clinical Epidemiology</i> , 2022, 146, 60-67.	2.4	0
8	Learning from COVID-19 related trial adaptations to inform efficient trial designâ€”a sequential mixed methods study. <i>BMC Medical Research Methodology</i> , 2022, 22, 128.	1.4	3
9	Treating Women with Recurrent Stress Urinary Incontinence: A Hornetâ€™s Nest Still Needing Proper Clinical Evidence. <i>European Urology</i> , 2021, 79, 6-7.	0.9	5
10	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
11	Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer. <i>Cancers</i> , 2021, 13, 825.	1.7	7
12	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luoâ€™s Letter to the Editor re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. <i>Eur Urol</i> 2020;78:701â€“10. <i>European Urology</i> , 2021, 79, e89-e90.	0.9	0
13	Protocol for an â€œefficient designâ€” cluster randomised controlled trial to evaluate a complex intervention to improve antibiotic prescribing for CHildren presenting to primary care with acute COugh and respiratory tract infection: the CHICO study. <i>BMJ Open</i> , 2021, 11, e041769.	0.8	3
14	Effective management of male lower urinary tract symptoms in primary care. <i>British Journal of General Practice</i> , 2021, 71, 388-389.	0.7	1
15	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2021, 20, 895-906.	4.9	26
16	Losartan to slow the progression of mild-to-moderate Alzheimerâ€™s disease through angiotensin targeting: the RADAR RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-72.	0.9	3
17	Best-BRA (Is subpectoral or prepectoral implant placement best in immediate breast reconstruction?): a protocol for a pilot randomised controlled trial of subpectoral versus prepectoral immediate implant-based breast reconstruction in women following mastectomy. <i>BMJ Open</i> , 2021, 11, e050886.	0.8	2
18	A third trial oversight committee: Functions, benefits and issues. <i>Clinical Trials</i> , 2020, 17, 106-112.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Reply to Sachin Malde, Arun Sahai, and Eskinder Solomon's Letter to the Editor re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. <i>Eur Urol</i> 2020;78:701-10. <i>European Urology</i> , 2020, 78, e234-e235.	0.9	1
20	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1063-1070.	2.9	15
21	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020, 10, e036024.	0.8	7
22	Quality control of uroflowmetry and urodynamic data from two large multicenter studies of male lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020, 39, 1170-1177.	0.8	25
23	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020, 31, 431-449.	0.8	53
24	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
25	Thulium laser transurethral vaporesction of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 50-61.	6.3	22
26	Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. <i>European Urology</i> , 2020, 78, 701-710.	0.9	36
27	The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesction of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction. <i>BJU International</i> , 2020, 126, 595-603.	1.3	6
28	Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study. <i>Trials</i> , 2020, 21, 304.	0.7	24
29	Grading Severity and Bother Using the International Prostate Symptom Score and International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Score in Men Seeking Lower Urinary Tract Symptoms Therapy. <i>Journal of Urology</i> , 2020, 204, 1003-1011.	0.2	15
30	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
31	Thulium laser transurethral vaporesction versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-96.	1.3	6
32	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-122.	1.3	21
33	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1011-1011.	0.2	0
34	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 200-213.	2.4	6
35	Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). <i>European Urology Focus</i> . 2019. 5. 340-350.	1.6	23
36	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30

#	ARTICLE	IF	CITATIONS
37	TreatIng Urinary symptoms in Men in Primary Healthcare using non-pharmacological and non-surgical interventions (TRIUMPH) compared with usual care: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2019, 20, 546.	0.7	8
38	Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1067-1075.	1.2	23
39	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF1, IGF2, IGFBP1, IGFBP2 and IGFBP3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	2.3	14
40	Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer. <i>BMJ Open</i> , 2019, 9, e029480.	0.8	9
41	Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial. <i>International Journal of Cancer</i> , 2019, 144, 1918-1928.	2.3	37
42	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 883.	3.8	296
43	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018, 52, 99-105.	0.8	8
44	Systematic review evaluating randomized controlled trials of smoking and alcohol cessation interventions in people with head and neck cancer and oral dysplasia. <i>Head and Neck</i> , 2018, 40, 1845-1853.	0.9	23
45	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018, 29, 383-388.	0.8	15
46	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16
47	Clinical- and cost-effectiveness of the STAR care pathway compared to usual care for patients with chronic pain after total knee replacement: study protocol for a UK randomised controlled trial. <i>Trials</i> , 2018, 19, 132.	0.7	20
48	Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets. <i>PLoS ONE</i> , 2018, 13, e0204886.	1.1	27
49	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 687-696.	0.7	32
50	"Recruitment, recruitment, recruitment" - the need for more focus on retention: a qualitative study of five trials. <i>Trials</i> , 2018, 19, 76.	0.7	41
51	Barriers and facilitators to healthy lifestyle and acceptability of a dietary and physical activity intervention among African Caribbean prostate cancer survivors in the UK: a qualitative study. <i>BMJ Open</i> , 2017, 7, e017217.	0.8	23
52	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin Targeting (RADAR) Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 803-814.	1.2	28
53	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017, 28, 877-888.	0.8	2
54	A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporessection of the prostate (ThuVAP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) - the UNBLOCS trial: a study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 179.	0.7	13

#	ARTICLE	IF	CITATIONS
55	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	0.9	11
56	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
57	Acceptability of dietary and physical activity lifestyle modification for men following radiotherapy or radical prostatectomy for localised prostate cancer: a qualitative investigation. <i>BMC Urology</i> , 2017, 17, 94.	0.6	17
58	Identifying research priorities for effective retention strategies in clinical trials. <i>Trials</i> , 2017, 18, 406.	0.7	38
59	Statistical analysis plan for the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). <i>Trials</i> , 2017, 18, 455.	0.7	12
60	A cohort examination to establish reporting of the remit and function of Trial Steering Committees in randomised controlled trials. <i>Trials</i> , 2017, 18, 590.	0.7	1
61	“We all want to succeed, but we’ve also got to be realistic about what is happening”: an ethnographic study of relationships in trial oversight and their impact. <i>Trials</i> , 2017, 18, 612.	0.7	6
62	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e017729.	0.8	27
63	What are the roles and valued attributes of a Trial Steering Committee? Ethnographic study of eight clinical trials facing challenges. <i>Trials</i> , 2016, 17, 307.	0.7	16
64	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016, 118, 911-918.	1.3	5
65	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
66	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
67	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016, 118, 869-879.	1.3	52
68	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016, 27, 1465-1474.	0.8	17
69	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016, 115, 90-94.	2.9	38
70	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016, 17, 497.	0.7	5
71	Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial. <i>Trials</i> , 2016, 17, 123.	0.7	14
72	Urodynamic Testing for Men with Voiding Symptoms Considering Interventional Therapy: The Merits of a Properly Constructed Randomised Trial. <i>European Urology</i> , 2016, 69, 759-760.	0.9	5

#	ARTICLE	IF	CITATIONS
73	One-stage or two-stage revision surgery for prosthetic hip joint infection – the INFORM trial: a study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 90.	0.7	66
74	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1875-1891.	0.7	7
75	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016, 25, 2377-2393.	0.7	23
76	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015, 5, e008953.	0.8	18
77	Exploring the role and function of trial steering committees: results of an expert panel meeting. <i>Trials</i> , 2015, 16, 597.	0.7	23
78	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015, 137, 1509-1515.	2.3	25
79	Trial Steering Committees in randomised controlled trials: A survey of registered clinical trials units to establish current practice and experiences. <i>Clinical Trials</i> , 2015, 12, 664-676.	0.7	24
80	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015, 26, 205-218.	0.8	33
81	How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. <i>European Urology</i> , 2015, 67, 637-645.	0.9	105
82	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 993-1005.	0.9	96
83	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015, 15, 80.	0.9	16
84	Gleason drift in the <sc>NIHR ProtecT</sc> study. <i>Histopathology</i> , 2015, 66, 438-446.	1.6	9
85	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015, 10, e0136735.	1.1	6
86	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015, 3, 1-138.	1.4	4
87	Adherence to Dietary and Lifestyle Recommendations and Prostate Cancer Risk in the Prostate Testing for Cancer and Treatment (ProtecT) Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2066-2077.	1.1	33
88	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1109-1118.	5.1	205
89	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014, 15, 81.	2.9	40
90	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013, 24, 39-45.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013, 24, 323-334.	0.8	30
92	Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Caseâ€“Control Study ProtecT. <i>Cancer Research</i> , 2012, 72, 503-515.	0.4	50
93	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ: British Medical Journal</i> , 2012, 344, d7894-d7894.	2.4	211
94	Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1877-1885.	1.1	19
95	Associations of circulating 25â€“hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012, 131, 1187-1196.	2.3	63
96	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study. <i>Cancer Causes and Control</i> , 2012, 23, 575-588.	0.8	20
97	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012, 23, 907-917.	0.8	32
98	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 628-636.	2.4	18
99	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1127-1136.	2.4	93
100	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011, 108, 1409-1414.	1.3	6
101	Association of diabetes mellitus with prostate cancer: Nested caseâ€“control study (Prostate testing) Tj ETQq1 1 0,784314 rgBT /Over	2.3	56
102	Associations of aspirin, nonsteroidal antiâ€“inflammatory drug and paracetamol use with PSAâ€“detected prostate cancer: Findings from a large, populationâ€“based, caseâ€“control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011, 128, 1442-1448.	2.3	41
103	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 316-27.	0.4	9
104	The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010, 21, 1829-1842.	0.8	26
105	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. <i>European Urology</i> , 2010, 57, 446-452.	0.9	12
106	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2833-2838.	1.1	20
107	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1632-1642.	1.1	142
108	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009, 14, 77-81.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2874-2881.	1.1	64
110	It's not just what you say, it's also how you say it: Opening the "black box" of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009, 68, 2018-2028.	1.8	154
111	Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009, 125, 1414-1423.	2.3	49
112	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for) Tj ETQq0 0 0 rgBTL3 Overlods 10 Tf 50		
113	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 29-36.	2.4	133
114	Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. <i>European Urology</i> , 2008, 53, 1186-1193.	0.9	41
115	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 1139.	2.4	18
116	Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2006, 332, 199-204.	2.4	54
117	What accompanies a postal questionnaire and why does it matter?. <i>International Journal of Public Health</i> , 2004, 49, 413-415.	2.7	1
118	Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. <i>BMJ: British Medical Journal</i> , 2004, 328, 1417.	2.4	11
119	A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population:. <i>Contemporary Clinical Trials</i> , 2002, 23, 321-332.	2.0	31
120	Effect of Helicobacter pylori infection on blood pressure: a community based cross sectional study. <i>BMJ: British Medical Journal</i> , 2001, 323, 264-265.	2.4	20